apnea has been researched along with Cerebral Palsy in 13 studies
Apnea: A transient absence of spontaneous respiration.
Cerebral Palsy: A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines." | 9.41 | Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 9.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 9.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation." | 8.82 | Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005) |
| "The neurodevelopmental outcome of premature infants with persistent apnea of prematurity (AOP) is reported." | 7.68 | Neurodevelopmental outcome of infants with apnea of infancy. ( Hegyi, T; Hiatt, M; Jadeja, N; Koons, AH; Mojica, N; Ostfeld, B, 1993) |
| " Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines." | 5.41 | Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 5.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 5.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation." | 4.82 | Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005) |
| " Subjects with CP had greater variability and duration of deglutition apnea than controls." | 3.73 | The effect of viscosity on the breath-swallow pattern of young people with cerebral palsy. ( Moussavi, Z; Rempel, G, 2005) |
| " Perioperative complications were postanesthetic seizure and postoperative brief apnea." | 3.71 | [Anesthetic management for laryngotracheal separation and tracheoesophageal diversion]. ( Kujime, Y; Obara, H; Okada, N; Sakai, K; Shiga, M; Takekida, S, 2002) |
| "The neurodevelopmental outcome of premature infants with persistent apnea of prematurity (AOP) is reported." | 3.68 | Neurodevelopmental outcome of infants with apnea of infancy. ( Hegyi, T; Hiatt, M; Jadeja, N; Koons, AH; Mojica, N; Ostfeld, B, 1993) |
| " This study also identified a short-latency apnea that appears to accompany a saliva (protective) swallow and a long-latency apnea that accompanies semi-solid or liquid bolus (alimentary) swallows." | 3.67 | Correlation of ultrasound imaging of oral swallow with ventilatory alterations in cerebral palsied and normal children: preliminary observations. ( Casas, MJ; Kenny, DJ; McPherson, KA, 1989) |
| "Babies with seizures, as well as those with terminal apnoea, were also substantially more likely than controls to have been born after a failure to react appropriately to signs of severe fetal distress during labour." | 2.65 | Adverse outcome of pregnancy and the quality of obstetric care. ( Chalmers, I; Elbourne, D; Henson, G; Macfarlane, A; Niswander, K; Redman, C; Tizard, P, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Marques, KA | 1 |
| Bruschettini, M | 1 |
| Roehr, CC | 1 |
| Davis, PG | 3 |
| Fiander, M | 1 |
| Soll, R | 1 |
| Mohon, RT | 1 |
| Khan, E | 1 |
| DelRosso, LM | 1 |
| Schmidt, B | 3 |
| Anderson, PJ | 1 |
| Doyle, LW | 3 |
| Dewey, D | 1 |
| Grunau, RE | 1 |
| Asztalos, EV | 1 |
| Tin, W | 2 |
| Moddemann, D | 1 |
| Solimano, A | 2 |
| Ohlsson, A | 2 |
| Barrington, KJ | 2 |
| Roberts, RS | 2 |
| Takekida, S | 1 |
| Okada, N | 1 |
| Kujime, Y | 1 |
| Sakai, K | 1 |
| Shiga, M | 1 |
| Obara, H | 1 |
| Rempel, G | 1 |
| Moussavi, Z | 1 |
| Davis, P | 1 |
| Niswander, K | 1 |
| Henson, G | 1 |
| Elbourne, D | 1 |
| Chalmers, I | 1 |
| Redman, C | 1 |
| Macfarlane, A | 1 |
| Tizard, P | 1 |
| Koch, B | 1 |
| Braillier, D | 1 |
| Eng, G | 1 |
| Binder, H | 1 |
| Koons, AH | 1 |
| Mojica, N | 1 |
| Jadeja, N | 1 |
| Ostfeld, B | 1 |
| Hiatt, M | 1 |
| Hegyi, T | 1 |
| Tamura, F | 1 |
| Shishikura, J | 1 |
| Mukai, Y | 1 |
| Kaneko, Y | 1 |
| Rickards, AL | 1 |
| Kelly, EA | 1 |
| Ford, GW | 1 |
| Davis, NM | 1 |
| Callanan, C | 1 |
| Kenny, DJ | 1 |
| Casas, MJ | 1 |
| McPherson, KA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182] | Phase 2/Phase 3 | 7 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Low recruitment rate) | ||
| Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity[NCT01020357] | Phase 3 | 201 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [NCT01066728] | Phase 2/Phase 3 | 87 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates[NCT03086473] | Phase 4 | 24 participants (Actual) | Interventional | 2017-02-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for apnea and Cerebral Palsy
| Article | Year |
|---|---|
Methylxanthine for the prevention and treatment of apnea in preterm infants.
Topics: Apnea; Caffeine; Cerebral Palsy; Disabled Persons; Humans; Infant; Infant, Newborn; Infant, Prematur | 2023 |
Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial.
Topics: Aging; Apnea; Blindness; Cerebral Palsy; Cognition Disorders; Deafness; Follow-Up Studies; Humans; I | 2005 |
3 trials available for apnea and Cerebral Palsy
| Article | Year |
|---|---|
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Adverse outcome of pregnancy and the quality of obstetric care.
Topics: Adolescent; Apnea; Asphyxia Neonatorum; Birth Injuries; Cerebral Palsy; Clinical Trials as Topic; En | 1984 |
8 other studies available for apnea and Cerebral Palsy
| Article | Year |
|---|---|
Increasingly Familiar Breathing Pattern in an Unfamiliar Population. Sleep-related Breathing Disorders in High-Risk Patients.
Topics: Apnea; Baclofen; Cerebral Palsy; Child; Female; Humans; Polysomnography; Sleep; Sleep Apnea, Central | 2020 |
[Anesthetic management for laryngotracheal separation and tracheoesophageal diversion].
Topics: Adolescent; Anastomosis, Surgical; Anesthesia, General; Apnea; Cerebral Palsy; Child; Child, Prescho | 2002 |
The effect of viscosity on the breath-swallow pattern of young people with cerebral palsy.
Topics: Adolescent; Adult; Analysis of Variance; Apnea; Case-Control Studies; Cerebral Palsy; Deglutition; D | 2005 |
Computerized tomography in cerebral-palsied children.
Topics: Adolescent; Apnea; Brain; Cerebral Palsy; Child; Child, Preschool; Hemiplegia; Humans; Infant; Infan | 1980 |
Neurodevelopmental outcome of infants with apnea of infancy.
Topics: Apnea; Cerebral Palsy; Child, Preschool; Developmental Disabilities; Female; Follow-Up Studies; Huma | 1993 |
Arterial oxygen saturation in severely disabled people: effect of oral feeding in the sitting position.
Topics: Adolescent; Adult; Airway Obstruction; Apnea; Blood Circulation; Cerebral Palsy; Cough; Disabled Per | 1999 |
Methylxanthines and sensorineural outcome at 14 years in children < 1501 g birthweight.
Topics: Adolescent; Apnea; Bronchodilator Agents; Cerebral Palsy; Child Development; Developmental Disabilit | 2000 |
Correlation of ultrasound imaging of oral swallow with ventilatory alterations in cerebral palsied and normal children: preliminary observations.
Topics: Apnea; Cerebral Palsy; Deglutition; Humans; Respiration; Ultrasonography | 1989 |